Tali Digital Ltd
ASX:TD1
Tali Digital Ltd
Tali Digital Ltd. engages in the development and commercialization of products in the emerging health technology sector. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-23. The firm is engaged in early childhood technology business targeting in children through its Tali platform. The firm has built a platform technology, the first iteration of which targets cognitive attention skills during early childhood through its video-gamed-based TALi screening (DETECT) and training (TRAIN). TALi are a software as a service (SaaS) model delivered via business to business (B2B) partnership and licensing models globally. The firm is engaged in delivering a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) for predictive diagnosis and treatment for all age groups along with a core research program exploring applications for at populations afflicted with Mild Cognitive Decline (MCI), which has been found to often been a precursor to recognizing Alzheimer’s disease and other forms of dementia.
Tali Digital Ltd. engages in the development and commercialization of products in the emerging health technology sector. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-23. The firm is engaged in early childhood technology business targeting in children through its Tali platform. The firm has built a platform technology, the first iteration of which targets cognitive attention skills during early childhood through its video-gamed-based TALi screening (DETECT) and training (TRAIN). TALi are a software as a service (SaaS) model delivered via business to business (B2B) partnership and licensing models globally. The firm is engaged in delivering a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) for predictive diagnosis and treatment for all age groups along with a core research program exploring applications for at populations afflicted with Mild Cognitive Decline (MCI), which has been found to often been a precursor to recognizing Alzheimer’s disease and other forms of dementia.
